Drug Profile
Research programme: cancer vaccines - Bavarian Nordic
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bavarian Nordic
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Denmark
- 03 Mar 2011 Early research in Cancer in Denmark (unspecified route)